Lynall, Mary-Ellen http://orcid.org/0000-0002-1939-7525
Soskic, Blagoje http://orcid.org/0000-0003-3173-4528
Hayhurst, James
Schwartzentruber, Jeremy
Levey, Daniel F. http://orcid.org/0000-0001-8431-9569
Pathak, Gita A.
Polimanti, Renato http://orcid.org/0000-0003-0745-6046
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Stein, Murray B. http://orcid.org/0000-0001-9564-2871
Trynka, Gosia http://orcid.org/0000-0002-6955-9529
Clatworthy, Menna R.
Bullmore, Ed
Funding for this research was provided by:
RCUK | Medical Research Council (MR/S006257/1)
DH | National Institute for Health Research (Senior Investigator award to Ed Bullmore)
Wellcome Trust (WT206194)
Article History
Received: 5 November 2021
Accepted: 6 October 2022
First Online: 15 October 2022
Competing interests
: E.T.B. serves as a member of the scientific advisory boards of Sosei Heptares, Boehringer Ingelheim, Monument Therapeutics, and the Brain & Behavior Research Foundation, and as a consultant for GlaxoSmithKline; he is also a Deputy Editor of <i>Biological Psychiatry</i>. J.G. and R.P. are paid for their editorial work for Complex Psychiatry journal. M.B.S. in the past 3 years has received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, Boehringer Ingelheim, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, Engrail Therapeutics, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech. M.B.S. has stock options in Oxeia Biopharmaceuticals and EpiVario. He is paid for his editorial work on <i>Depression and</i> Anxiety (Editor-in-Chief), <i>Biological Psychiatry</i> (Deputy Editor), and <i>UpToDate</i> (Co-Editor-in-Chief for Psychiatry). He has also received research support from NIH, Department of Veterans Affairs, and the Department of Defense. He is on the scientific advisory board for the Brain and Behavior Research Foundation and the Anxiety and Depression Association of America. The remaining authors declare no competing interests.